Travere Therapeutics, Inc. filings document a rare-disease biopharmaceutical issuer whose disclosures center on FILSPARI (sparsentan), operating results, FDA regulatory events, and public-company governance. Recent 8-K reports furnish quarterly and annual financial results and disclose regulatory events involving FILSPARI in focal segmental glomerulosclerosis and IgA nephropathy.
Proxy materials cover annual meeting voting, board matters, executive compensation, equity awards, and stockholder governance. The filing record also documents formal event reporting under the Exchange Act for product-regulatory updates and financial-condition disclosures.
Travere Therapeutics, Inc. (TVTX) is identified as the issuer for Officer Sandra Calvin’s proposed sale of 21,977 common shares, with an aggregate market value of $902,595.39 and an approximate sale date of April 14, 2026. Morgan Stanley Smith Barney LLC is listed as the broker. The notice gives June 10, 2025 as the date of plan adoption or instruction, if relying on Rule 10b5-1. The shares listed for sale were acquired through restricted stock awards of 1,263 shares on January 21, 2025 and 5,464 shares on January 31, 2025, plus a 15,250-share stock option exercise on April 14, 2026. Calvin also reported selling 4,333 common shares on February 3, 2026, for gross proceeds of $139,177.16 during the preceding three months.
Travere Therapeutics reported that the FDA approved FILSPARI (sparsentan) to reduce proteinuria in adults and children 8 years and older with focal segmental glomerulosclerosis (FSGS) without nephrotic syndrome. FILSPARI is now the first and only FDA‑approved medicine specifically for FSGS, expanding its use beyond IgA nephropathy into a second rare kidney disease.
The company estimates a U.S. addressable population of more than 30,000 FSGS patients without nephrotic syndrome. In the Phase 3 DUPLEX study, FILSPARI cut proteinuria by 46% from baseline to Week 108 in the overall population versus 30% with irbesartan, and by 48% versus 27% in patients without nephrotic syndrome, with statistically significant results. FILSPARI also showed a modest eGFR benefit and was generally well tolerated with a safety profile comparable to irbesartan.
TeleVox Media, Inc. submitted a Form 144 notice regarding proposed sales of 65 shares of Common Stock tied to restricted stock unit vesting on 04/10/2026. The filing lists 92,241,550 shares outstanding as of 04/13/2026 and records prior sales by Christopher Cline of 1,745 shares and 7,242 shares in February 2026.
Travere Therapeutics director Roy D. Baynes exercised and sold shares in a planned transaction. On April 6, 2026, he exercised stock options for 10,000 shares of Common Stock at an exercise price of $26.52 per share and received 10,000 shares.
That same day, he completed an open-market sale of 10,000 Common Stock shares at $33.00 per share under a pre-arranged Rule 10b5-1 trading plan adopted on November 17, 2025. Following these transactions, Baynes directly holds 37,500 Common Stock shares.
Travere Therapeutics, Inc. is asking stockholders to vote at its 2026 Annual Meeting on May 19, 2026 at the company’s San Diego headquarters. Stockholders of record at the close of business on March 23, 2026, when 92,369,812 common shares were outstanding, may vote.
Key items include electing ten directors for one-year terms, approving an amendment to the 2018 Equity Incentive Plan to add 3,000,000 shares for equity awards, advisory approval of executive compensation and the preferred frequency of say‑on‑pay votes, and ratification of Ernst & Young LLP as independent auditor for the year ending December 31, 2026.
The proxy also details board independence, committee responsibilities, board risk oversight (including cybersecurity and ESG), and significant stockholder and management ownership levels, such as several institutions each holding more than 5% of outstanding shares as of March 2, 2026.
Travere Therapeutics CEO Eric M. Dube exercised stock options covering 60,000 shares of common stock at $15.46 per share on April 1, 2026, then sold the same 60,000 shares in the open market.
The sales were split between 34,902 shares at $30.55 and 25,098 shares at $31.46, executed under a pre-arranged Rule 10b5-1(c) trading plan adopted on June 16, 2025. After these transactions, Dube directly holds 432,886 shares of Travere common stock.
Travere Therapeutics Chief Legal Officer Elizabeth E. Reed exercised employee stock options and sold shares in a planned transaction. She exercised options for 10,000 shares of common stock at $15.46 per share and then sold 10,000 shares at $30.00 per share on the same day. After these transactions, she directly holds 105,211 shares of Travere Therapeutics common stock. The filing notes the sale was made under a written plan adopted on June 16, 2025 that meets Rule 10b5-1(c) requirements, and that the underlying stock option grant from January 31, 2020 is fully vested and exercisable.
TVTX filed a Form 144 disclosing the intended sale of 60,000 shares of Common Stock on 04/01/2026. The filing lists the sale method as cash and records several prior dispositions in the past three months: 8,135; 51,865; 100,087; and 60,000 shares on specified dates.